(19)
(11) EP 3 448 879 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.04.2025 Bulletin 2025/16

(45) Mention of the grant of the patent:
26.02.2025 Bulletin 2025/09

(21) Application number: 17722139.7

(22) Date of filing: 28.04.2017
(51) International Patent Classification (IPC): 
C07K 14/47(2006.01)
A61P 35/00(2006.01)
G01N 33/68(2006.01)
C07K 14/74(2006.01)
 A61K 38/00(2006.01)
G01N 33/574(2006.01)
C07K 14/725(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/4748; A61K 38/00; G01N 33/574; G01N 33/6878; G01N 2333/70539; G01N 2500/02; A61P 35/00; C07K 14/7051; C07K 14/70539
(86) International application number:
PCT/GB2017/051193
(87) International publication number:
WO 2017/187186 (02.11.2017 Gazette 2017/44)

(54)

CLAUDIN-6 PEPTIDES

CLAUDIN-6-PEPTIDE

PEPTIDES DE CLAUDINE -6

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 29.04.2016 GB 201607534

(43) Date of publication of application:
06.03.2019 Bulletin 2019/10

(73) Proprietor: Immunocore Limited
Abingdon, Oxfordshire OX14 4RY (GB)

(72) Inventors:
  • POWLESLAND, Alex
    Abingdon Oxfordshire OX14 4RY (GB)
  • SUN, Mei
    Abingdon Oxfordshire OX14 4RY (GB)

(74) Representative: Lee, Nicholas John et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)


(56) References cited: : 
WO-A1-2015/150327
WO-A1-2015/150327
WO-A2-01/62891
WO-A2-2008/021290
WO-A2-2008/021290
WO-A2-2008/116468
WO-A2-2009/130588
US-A1- 2008 207 497
US-A1- 2017 056 487
 WO-A1-2015/150327
WO-A2-01/62891
WO-A2-01/62891
WO-A2-2008/021290
WO-A2-2008/116468
WO-A2-2009/130588
US-A1- 2008 207 497
US-A1- 2017 056 487
US-A1- 2017 056 487
   
  • DATABASE Geneseq [online] 2 April 2009 (2009-04-02), "BK virus antigen class I peptide SEQ ID NO:3416.", XP002797719, retrieved from EBI accession no. GSP:AWC11355 Database accession no. AWC11355
  • DATABASE Geneseq [online] 10 December 2009 (2009-12-10), "T cell epitope (TCE) SEQ ID:921.", XP002797718, retrieved from EBI accession no. GSP:AXR88241 Database accession no. AXR88241
  • DATABASE Geneseq [online] 2 April 2009 (2009-04-02), "BK virus antigen class I peptide SEQ ID NO:3416.", XP002797719, retrieved from EBI accession no. GSP:AWC11355 Database accession no. AWC11355
  • DATABASE Geneseq [online] 10 December 2009 (2009-12-10), "T cell epitope (TCE) SEQ ID:921.", XP002797718, retrieved from EBI accession no. GSP:AXR88241 Database accession no. AXR88241
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).